National Biotechnology Research Park

IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event

Retrieved on: 
Tuesday, August 1, 2023
Therapy, SAN, National Biotechnology Research Park, Medicine, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Aug. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
  • Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst
    A live audio webcast of the conference event will be available through the conference host.

Indaptus Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference

Retrieved on: 
Thursday, June 15, 2023
Charles M. Vest, Biotechnology, Research, Therapy, Senior, Patient, Conference, National Biotechnology Research Park, Pharmaceutical industry

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler will participate in the Maxim Group Virtual Healthcare Conference presented by Maxim Group and hosted by M-Vest.

Key Points: 
  • NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler will participate in the Maxim Group Virtual Healthcare Conference presented by Maxim Group and hosted by M-Vest.
  • The conference is being held virtually on June 20 – 22, 2023.
  • Mr. Meckler will participate in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group on June 21 at 10:30am ET.
  • Investors can register and watch the discussion on the M-Vest page:

AESOP Technology Announces Collaboration with AstraZeneca Taiwan on Medigator: Advancing Shared Decision-Making in Precision Medicine

Retrieved on: 
Friday, June 2, 2023
Communication, Partnership, National Biotechnology Research Park, Computerized physician order entry, Big data, American Society of Clinical Oncology, Cancer, Risk management, Quality of life, Research, American Cancer Society, Immunotherapy, AstraZeneca, Patient, Data, Physician, Risk, Immune system, Medicine, Death, Society, Medical device, Vaccine, Nursing, Pharmaceutical industry, Robert Ira Lewy

CHICAGO, June 2, 2023 /PRNewswire/ -- AESOP Technology , in collaboration with AstraZeneca Taiwan, has unveiled Medigator , an innovative AI software designed to manage immune-related adverse events (irAEs) and enhance the effectiveness of immunotherapy.

Key Points: 
  • CHICAGO, June 2, 2023 /PRNewswire/ -- AESOP Technology , in collaboration with AstraZeneca Taiwan, has unveiled Medigator , an innovative AI software designed to manage immune-related adverse events (irAEs) and enhance the effectiveness of immunotherapy.
  • While this treatment stimulates the patient's immune system to fight cancer, it can potentially trigger an overactive immune response, leading to irAEs.
  • Medigator has set a promising example demonstrating patient-centric innovation by advancing shared decision-making in precision medicine," said Ben Chen, Medical Director, AstraZeneca Taiwan.
  • AESOP Technology continues its unwavering commitment to delivering physicians with precise and personalized solutions for irAEs as immunotherapy advances.

Food Innovators Highlight Policy Priorities at First-Ever Capitol Hill Fly-In & Reception

Retrieved on: 
Tuesday, April 25, 2023
Workforce, National Biotechnology Research Park, The Good Food Institute, Food, Poultry, Farmer, Agriculture, Policy, Specialty Food Association, Saint-Just, Seafood, GFI, Finless Foods, Research, Multimedia, Government, Organization, United States farm bill, Congress, Climate change, Investment, Climate, Federation, Health, Meat, Food security, Impossible Foods, Egg, Renewable energy

The group hosted policymakers, regulators and media at an invite-only event on Capitol Hill where guests enjoyed hors d'oeuvres featuring ingredients from the emerging food brands, curated by popular deli and caterer DC Vegan .

Key Points: 
  • The group hosted policymakers, regulators and media at an invite-only event on Capitol Hill where guests enjoyed hors d'oeuvres featuring ingredients from the emerging food brands, curated by popular deli and caterer DC Vegan .
  • "The Good Food Institute is working to create a world where alternative proteins are no longer alternative.
  • Along with our industry partners, including the companies that convened on Capitol Hill today, GFI looks forward to sharing its policy priorities with Congressional leaders," said Bruce Friedrich, founder and president of GFI.
  • Innovators and leaders in the industry are recommending that the U.S. government:
    Invest in the future of food through research, development and consumer education.

Liberation Labs Secures $30 Million in Equipment Funding for First Biomanufacturing Facility

Retrieved on: 
Wednesday, April 12, 2023
Biotechnology, CPG, Engineering, National Biotechnology Research Park, Food, Health, Bioproduct, Fermentation, DSP, Fine chemical

RICHMOND, Ind., April 12, 2023 (GLOBE NEWSWIRE) -- Liberation Labs , industrial biotech’s fabrication partner, has secured $30 million in equipment financing to advance development of its first commercial-scale biomanufacturing facility in Richmond, Indiana.

Key Points: 
  • RICHMOND, Ind., April 12, 2023 (GLOBE NEWSWIRE) -- Liberation Labs , industrial biotech’s fabrication partner, has secured $30 million in equipment financing to advance development of its first commercial-scale biomanufacturing facility in Richmond, Indiana.
  • The new facility will have a fermentation capacity of 600,000 liters with a fully dedicated downstream process (DSP).
  • Groundbreaking is expected in June 2023 with initial plant startup by the end of 2024.
  • The new facility will be the first purpose-built commercial-scale precision fermentation plant in the United States.

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

Retrieved on: 
Thursday, March 9, 2023
Conference, Oppenheimer, National Biotechnology Research Park, Cryptocurrency, Tobacco, Management

CUPERTINO, Calif., March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.

Key Points: 
  • CUPERTINO, Calif., March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participate in a fireside chat hosted by Francois Brisebois, Managing Director, Senior Biotechnology Research Analyst at Oppenheimer & Co. Inc. at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15th, 2023.
  • Presentation details are as follows:

Bugworks Research Inc welcomes Dr. Renu Swarup to its Global Advisory Board

Retrieved on: 
Wednesday, February 22, 2023
Tobacco Products Scientific Advisory Committee, Department of Biotechnology, Cancer, National academy, Woman, DBT, Organization, NASI, Public sector, Joint FAO/WHO Expert Committee on Food Additives, Patient, BIRAC, SME, Ministry, AMR, Public, Developing country, National Science Advisory Board for Biosecurity, Infection, Organization for Women in Science for the Developing World, National Biotechnology Research Park, COVID-19, Advisory board, Pharmaceutical industry, Biotechnology, Science

BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 22, 2023 /PRNewswire/ -- Bugworks Research, a clinical-stage biopharmaceutical company, has engaged Dr. Renu Swarup as a honorary member of the Global Advisory Board. Dr. Swarup is the former Secretary, Department of Biotechnology, Government of India and brings in more than three decades of experience in the biotech sector. 

Key Points: 
  • Former secretary of the Department of Biotechnology, Government of India and reputed Biotechnologist joins the Advisory Board to provide strategic guidance to the project portfolio of Bugworks Research
    BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 22, 2023 /PRNewswire/ -- Bugworks Research, a clinical-stage biopharmaceutical company, has engaged Dr. Renu Swarup as a honorary member of the Global Advisory Board.
  • Speaking on her appointment, Dr. Anand Anandkumar - CEO, Bugworks Research states, "Bugworks is pleased to welcome Dr. Renu Swarup as a member of its Global Advisory Board.
  • We look forward to working closely with Dr. Swarup to help us reach our goal of enabling equitable global access to Bugworks' innovative products."
  • On joining Bugworks Research, Dr. Renu Swarup said, "I am pleased to be associated with Bugworks in my capacity as an Honorary Advisor and member of their Global Advisory Board.

Bugworks Research Inc welcomes Dr. Renu Swarup to its Global Advisory Board

Retrieved on: 
Wednesday, February 22, 2023
Tobacco Products Scientific Advisory Committee, Department of Biotechnology, Cancer, National academy, Woman, DBT, Organization, NASI, Public sector, Joint FAO/WHO Expert Committee on Food Additives, Patient, BIRAC, SME, Ministry, AMR, Public, Developing country, National Science Advisory Board for Biosecurity, Infection, Organization for Women in Science for the Developing World, National Biotechnology Research Park, COVID-19, Advisory board, Pharmaceutical industry, Biotechnology, Science

BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 22, 2023 /PRNewswire/ -- Bugworks Research, a clinical-stage biopharmaceutical company, has engaged Dr. Renu Swarup as a honorary member of the Global Advisory Board. Dr. Swarup is the former Secretary, Department of Biotechnology, Government of India and brings in more than three decades of experience in the biotech sector. 

Key Points: 
  • Former secretary of the Department of Biotechnology, Government of India and reputed Biotechnologist joins the Advisory Board to provide strategic guidance to the project portfolio of Bugworks Research
    BANGALORE, India, SARATOGA, Calif. and ADELAIDE, Australia, Feb. 22, 2023 /PRNewswire/ -- Bugworks Research, a clinical-stage biopharmaceutical company, has engaged Dr. Renu Swarup as a honorary member of the Global Advisory Board.
  • Speaking on her appointment, Dr. Anand Anandkumar - CEO, Bugworks Research states, "Bugworks is pleased to welcome Dr. Renu Swarup as a member of its Global Advisory Board.
  • We look forward to working closely with Dr. Swarup to help us reach our goal of enabling equitable global access to Bugworks' innovative products."
  • On joining Bugworks Research, Dr. Renu Swarup said, "I am pleased to be associated with Bugworks in my capacity as an Honorary Advisor and member of their Global Advisory Board.

Microbial Fermentation Technology Market Trends/Analysis Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 16, 2022
Biotechnology, Pharmaceutical, Health, Genomatica, Metabolic engineering, SUB, National Biotechnology Research Park, Cargill, CSR, ABEC, CMOS, Cyclone, Agitation, Inactivated vaccine, Tropical cyclone engineering, SWOT, Fermentation, USD, Growth, Biopharmaceutical, Hormone, Fine chemical, Vaccine

The "Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Application (Antibiotics, Vaccines), by End-use (Biopharmaceutical Companies), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbial Fermentation Technology Market Size, Share & Trends Analysis Report by Application (Antibiotics, Vaccines), by End-use (Biopharmaceutical Companies), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Since fermentation is observed to be of utmost importance in the manufacturing of biopharmaceuticals, there is also a growing demand for microbial fermentation technology in biopharmaceutical manufacturing.
  • The newly installed solutions are expected to provide a faster turnaround time with high-growth microbial fermentation on large scale.
  • Furthermore, technological advances in microbial fermentation platforms are also expected to supplement the market growth.

Cell-Free Technology Is A Growing Trend In The Synthetic Biology Market

Retrieved on: 
Tuesday, November 1, 2022
Synthetic Genomics (company), Growth, Novozymes, DNA, National Biotechnology Research Park, Precigen, Research, Integrated DNA Technologies, Technology, Risk, Integration, Merck Group, COVID-19, Codexis, Synthetic biology, Government, Workforce, CAGR, NBBI, Escherichia coli, Company, Danaher Corporation, Biotechnology, Gene, Solution, Science, Fine chemical, Pharmaceutical industry, New England Biolabs

LONDON, Nov. 1, 2022 /PRNewswire/ -- Cell-Free Technology is gaining popularity in the synthetic biology market. In this cell-free technology, cell transcription and translation machinery are exploited to express only one or several genes of interest in vitro.  Many companies in the synthetic biology market are developing this method to gain large outputs in a small-time frame. For instance, in September 2020, OriCiro Genomics, a Japan-based genome technology company offering innovative products and services for synthetic biology, announced the launch of the OriCiro Cell-Free Cloning System, the world's first technology enabling cell-free amplification of large circular DNA, which eliminates the reliance on E. coli cloning.

Key Points: 
  • LONDON, Nov. 1, 2022 /PRNewswire/ --Cell-Free Technology is gaining popularity in the synthetic biology market.
  • Many companies in the synthetic biology market are developing this method to gain large outputs in a small-time frame.
  • As per the synthetic biology market overview , major players in the synthetic biology market are Thermo Fischer Scientific, Genscript, Integrated DNA Technologies, Amyris, Twist Bioscience Corporation, Novozymes, New England Biolabs, Synthetic Genomics, Ginkgo Bioworks, Intrexon, E. I.
  • North America was the largest region in the synthetic biology market and was worth $4.13 billion in 2021.